ByteDance, the Chinese owner of TikTok, is pushing deeper into artificial intelligence with Anew Labs, a drug-discovery unit that has begun presenting its AI-designed therapies at international conferences. The unit – also known as Anew Therapeutics or ByteDance AI Drug Discovery – operates from Shanghai, Singapore and San Jose, California. Its official website listed 36…
![2MM: AI Roundup – Roche and NVIDIA’s AI drug discovery factory and surgical robotics foundation model, Amazon’s nationwide health AI expansion, and Brown’s AI therapy ethics warning [March 2026]](https://01webmasters.com/wp-content/uploads/2026/04/2MM-AI-Roundup-–-Roche-and-NVIDIAs-AI-drug-discovery-768x434.png)
A major leap in computational drug development has emerged with Roche’s launch of its global AI factory, powered by more than 3,500 NVIDIA Blackwell GPUs. This hybrid-cloud system integrates artificial intelligence across both early-stage drug discovery and downstream manufacturing pipelines. By leveraging NVIDIA’s healthcare AI platform, Roche aims to scale biological modeling at a level…
Despite decades of progress in pharmaceutical R&D, the earliest phase of drug discovery—where molecules are conceived and designed—remains costly, inefficient, and burdened by high failure rates. Most experimental compounds never reach clinical development, and those that do often take over a decade and billions of dollars to bring to market. These bottlenecks are rooted in…
New AI capability enables structured, scalable contracting decisions amid accelerating global pricing complexity BASEL, Switzerland, March 3, 2026 /PRNewswire/ — Lyfegen, a global provider of innovative drug access, contracting and rebate management solutions, announced today the launch of its AI Contracting Companion. This AI solution is designed to support pharmaceutical organizations navigating through increasingly intricate…
Artificial Intelligence (AI) in Drug Discovery Market Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the next five years. Key factors driving this growth include the increasing need to lower drug development costs and timelines, the rising adoption of AI technologies within the…
